BioHarvest Sciences heads into its third-quarter report with a split personality that the market has so far refused to reconcile. Last quarter, management signed its first contract manufacturing deal, a 20-ton fragrance commitment worth $20 million to $30 million over 2027 and 2028, while simultaneously cutting full-year revenue guidance and resetting its VINIA consumer business. Investors chose to focus on the cut. The real question now is whether the core subscription franchise has stabilized enough to fund the manufacturing story without another round of disappointment.
The Street expects a loss of $0.16 per share on revenue of about $9.6 million. That revenue figure implies roughly 6% growth from the year-ago $9.1 million and, more tellingly, a sequential step up of about 9% from the $8.8 million reported last quarter, when year-over-year growth slowed to under 4%. The loss is expected to be wider than the $0.14 posted a year ago, though slightly narrower than last quarter's $0.17. In other words, consensus is betting on modest reacceleration rather than further slippage, which makes the top line the number that matters most.
That bet looks reasonable against management's reset outlook of $37 million to $40 million in total revenue for 2026, down from $42 million to $48 million, with VINIA trimmed to $33 million to $35 million. Management framed the reduction as a deliberate decision to pull back marketing in the face of double-digit inflation in Meta advertising costs, rather than as fading demand. This report is the first real test of that framing. Active customers flattened near 95,000 last quarter, and the company's levers for growth without heavy acquisition spending are pricing and product. The first VINIA price increase since 2021, up to 20% for new subscribers, and the September launch of a single-dose VINIA Daily format should begin showing up here. Revenue per customer rising while churn holds steady would validate the capital reallocation argument. A further drop in customers or another sequential stall would suggest the price hike is pushing buyers away.
Margins deserve equal attention. Gross margin has eased from 61% a year ago to 58% last quarter, and D2C EBITDA guidance swung from a projected gain to a loss of $1.5 million to $2.5 million. Pricing should help gross margin, so further erosion would be a warning sign. On the manufacturing side, management sharply narrowed the expected CDMO EBITDA loss to $1.5 million to $2.5 million and tightened CDMO revenue to $4 million to $5 million. Progress on the expanded Tate & Lyle sweetener work, the saffron program and any movement on the still-unnegotiated fragrance royalty would add substance to a pipeline whose revenue is weighted toward 2028.
The market's mood is decidedly sour. Shares have fallen 31% since the last report against a 5.4% decline in the S&P 500, and at $1.49 the stock trades less than half its 200-day moving average of $3.18, sitting just above its post-earnings low of $1.37. Sentiment has grown more bearish, with nearly 79% of readings negative versus about 60% ahead of last quarter. Cash, at $16.2 million at midyear, matters greatly given rising capital spending for the facility build-out and management's stated intent to avoid another equity raise.
The central issue is whether VINIA can deliver the implied sequential rebound with steadier margins. If pricing and the new format lift revenue toward consensus while cash burn stays contained, the reset starts to look like discipline. If not, the CDMO opportunity, however promising, risks being overshadowed by financing worries before it ever reaches meaningful revenue.